A Novel FGFR3‐Targeting Antibody‐Drug Conjugate Induces Tumor Cell Apoptosis through the cGAS–STING Pathway in Bladder Cancer
Advanced Science · 2026-01 · 13 (4)
DOI: 10.1002/advs.202509933 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Science, online erschienen am 30.10.2025. Verfasst von Shu Cui und 16 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Urology, The Second Hospital of Lanzhou University, Gansu Province Clinical Research Center for Urinary System Disease, Lanzhou, 730030,…. Hauptthemen laut MEDLINE: Urinary Bladder Neoplasms, Apoptosis, Receptor, Fibroblast Growth Factor, Type 3, Immunoconjugates. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Gansu Province Major Science and Technology Special Project, Key Research and Development Program of Gansu Province.
Abstract (Originalsprache)
Antibody‐drug conjugates (ADCs) emerge as a potent cancer therapeutic strategy by enabling precise antigen recognition and efficient intracellular delivery of cytotoxic payloads. In this study, 7‐ethyl‐9‐fluorocamptothecin (A2), a camptothecin derivative, which demonstrates potent tumor‐suppressive effects across cellular models, patient‐derived organoids (PDOs), and cell line‐derived xenograft/patient‐derived xenograft (CDX/PDX) models is identified. Through pull‐down/mass spectrometry analysis, MAD2L1 is identified as the direct target of A2. A2 specifically binds to the Lys73 site of MAD2L1, activating the cGAS‐STING pathway and thereby inducing apoptosis in bladder cancer cells. To address the dose‐limiting toxicity caused by A2's insufficient targeting capability, LZU‐WZLYCS01, a novel FGFR3‐targeting ADC for bladder cancer with A2 as its cytotoxic payload is developed. LZU‐WZLYCS01 exhibits precise FGFR3‐dependent targeting, with significantly reduced antitumor activity in both FGFR3‐knockout cell models and xenograft models. Moreover, in vivo fluorescence imaging demonstrates the potent tumor‐targeting capability of LZU‐WZLYCS01. LZU‐WZLYCS01 demonstrates remarkable bystander effects in an in vitro co‐culture model, along with potent tumor growth inhibition in PDOs and CDX/PDX models while maintaining favorable safety. Notably, LZU‐WZLYCS01 shows superior antitumor efficacy to gemcitabine‐cisplatin (GC) chemotherapy and maintains significant activity in GC‐resistant PDX models. These findings present a promising therapeutic candidate for targeted bladder cancer treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute of Urology, The Second Hospital of Lanzhou University, Gansu Province Clinical Research Center for Urinary System Disease, Lanzhou, 730030, China.
- School of Pharmacy, Lanzhou University, Lanzhou, 730030, China.
- Robotic Minimally Invasive Surgery Center, Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu, 610072, China.
- The Legorreta Cancer Center at Brown University, Department of Pathology and Laboratory Medicine, The Warren Albert Medical School of Brown University, Brown University Health, Providence, RI, USA.
ORCID-Profile: Zhiping Wang
Förderung
- National Natural Science Foundation of China
- Gansu Province Major Science and Technology Special Project
- Key Research and Development Program of Gansu Province
Zitieren
APA
Cui, S., Luo, X., Fan, G., Jiang, J., Wang, Y., Yang, E., Ma, J., Zhang, Z., Wang, Y., Wang, J., Wang, D., Wang, H., Cheng, L., Tian, J., Dong, Z., Liu, Y., & Wang, Z. (2026). A Novel FGFR3‐Targeting Antibody‐Drug Conjugate Induces Tumor Cell Apoptosis through the cGAS–STING Pathway in Bladder Cancer. Advanced Science, 13(4). https://doi.org/10.1002/advs.202509933
Vancouver
Cui S, Luo X, Fan G, Jiang J, Wang Y, Yang E, et al. A Novel FGFR3‐Targeting Antibody‐Drug Conjugate Induces Tumor Cell Apoptosis through the cGAS–STING Pathway in Bladder Cancer. Advanced Science. 2026;13(4). doi:10.1002/advs.202509933
BibTeX
@article{Cui2026,
author = {Cui, Shu and Luo, Xiongfei and Fan, Guangrui and Jiang, Jingqi and Wang, Yingru and Yang, Enguang and Ma, Jinpeng and Zhang, Ze and Wang, Yuhan and Wang, Juan and Wang, Dengtuo and Wang, Hanzhang and Cheng, Liang and Tian, Junqiang and Dong, Zhilong and Liu, Yingqian and Wang, Zhiping},
title = {A Novel FGFR3‐Targeting Antibody‐Drug Conjugate Induces Tumor Cell Apoptosis through the cGAS–STING Pathway in Bladder Cancer},
journal = {Advanced Science},
year = {2026},
volume = {13},
number = {4},
doi = {10.1002/advs.202509933}
}
EUVIMED